REGN up +1.66% percent Today $REGN High is at 386.00 and the Low 376.54 with current volume of 222,315.
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - 28 mins ago
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 384.04 (+6.20)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.25 (-0.08), SNY: 46.36 (+0.67), GNW: 8.33 (-0.08), REGN: 384.04 (+6.20)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 98.65 (+2.81), AMGN: 162.65 (+2.40), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 325.37 (+4.62), MNST: 106.81 (-1.58), ATI: 31.62 (-1.06), MON: 115.27 (+0.83), GMCR: 155.76 (+2.86), VMC: 65.16 (+0.05), EMR: 65.17 (+0.31), WDC: 97.40 (-0.30), VRSN: 60.51 (+0.71), URBN: 30.64 (-0.54), FSLR: 52.02 (+1.73), DE: 88.35 (-0.31), EXPE: 86.10 (+0.99), FLR: 66.20 (-0.09), FLS: 68.20 (+0.30), X: 36.98 (-0.59), ROK: 112.52 (+0.23), REGN: 384.04 (+6.20), MA: 84.97 (+0.17)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 116.76 (+0.83), GERN: 2.23 (-0.10), AMGN: 162.62 (+2.37), ABBV: 63.80 (+2.30), AEGR: 21.58 (unch), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 6:27PM CST
Regeneron Pharmaceuticals was down 6% today after releasing third-quarter earnings. While U.S. sales of its flagship drug Eylea rose 23% year over year in the third quarter and sales by its partner Bayer HealthCare outside the U.S. more than...
SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 5.79% Sell Off
Comtex SmarTrend(R) - Tue Nov 04, 3:51PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $368.45 to a high of $384.43. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $386.27 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 384.04 (+6.20)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.68 (-0.27), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 3:16PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 384.04 (+6.20)
Regeneron falls after paring Eylea sales outlook
AP - Tue Nov 04, 11:52AM CST
NEW YORK (AP) — Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue.
REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue Guidance
at The Street - Tue Nov 04, 10:10AM CST
Regeneron Pharmaceuticals (REGN) shares are falling following the release of its third quarter earnings report.
REGN: 384.04 (+6.20)
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter
at Investor's Business Daily - Tue Nov 04, 9:51AM CST
Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street's Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron's earnings,...
REGN: 384.04 (+6.20)
Stocks Tightly Mixed After Open; Alibaba Climbs On Q2 Results
at Investor's Business Daily - Tue Nov 04, 9:32AM CST
Stocks opened lower and quickly turned mixed Tuesday as earnings reports, soft oil prices and mixed economic data drove the bulk of early trade. The Dow Jones industrial average shed early losses and rose 0.1%. The Nasdaq narrowed its opening loss to...
HLF: 38.04 (+0.54), AFSI: 50.46 (+0.57), KORS: 69.49 (-0.46), FL: 54.70 (+0.20), REGN: 384.04 (+6.20), PCLN: 1,106.56 (+11.95), BABA: 116.06 (+1.50)
Regeneron Reports Third Quarter 2014 Financial and Operating Results
PR Newswire - Tue Nov 04, 5:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2014 and provided an update on development programs.
REGN: 384.04 (+6.20)
Big Cap 20: Health Care, Tech Stocks Rule The Roost
at Investor's Business Daily - Mon Nov 03, 4:58PM CST
Large-cap stocks often get labeled as boring because of overall sluggish price action, but the latest IBD Big Cap 20 list of leading large-cap growth is far from boring. Recent health care-related names like Alexion Pharmaceuticals (ALXN), Illumina...
LNKD: 227.73 (+4.69), ALXN: 194.86 (+1.05), ILMN: 189.51 (+3.16), REGN: 384.04 (+6.20), CRM: 63.80 (-0.17), CELG: 107.94 (+1.49)
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Mon Nov 03, 3:01PM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
REGN: 384.04 (+6.20)
Video: 4 Top-Rated Stocks Reporting Earnings Tuesday
at Investor's Business Daily - Mon Nov 03, 1:32PM CST
Alibaba, the world's largest IPO to date, is set to report its first quarterly earnings as a public company before the open on Tuesday. Analysts expect the Chinese e-commerce giant to earn 45 cents a share, excluding items, on revenue of $2.6...
JAZZ: 171.64 (+0.84), REGN: 384.04 (+6.20), BKW: 32.20 (-0.40), BABA: 116.06 (+1.50)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 86.77 (+2.86), ISIS: 45.99 (+1.40), SGEN: 36.16 (+0.11), GILD: 108.28 (+1.83), SSYS: 104.23 (+1.16), HP: 86.15 (-0.55), REGN: 384.04 (+6.20), CELG: 107.94 (+1.49)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 101.10 (+2.11), VRX: 127.62 (+1.51), BAX: 70.62 (+0.01), CVS: 88.94 (+0.56), REGN: 384.04 (+6.20)
Stocks End Week On Fine Note; LinkedIn Surges On Earnings
at Investor's Business Daily - Fri Oct 31, 3:29PM CDT
The market enjoyed another shot of institutional buying Friday, cheered by additional -- and unexpected -- stimulus measures by the Bank of Japan. Another round of healthy earnings reports and a rise in U.S. consumer confidence also fueled positive...
AMBA: 49.19 (+2.05), TSLA: 242.08 (+1.88), GPRO: 76.28 (-2.78), ACT: 247.66 (+1.75), FRGI: 56.39 (+0.80), LNKD: 227.73 (+4.69), JAZZ: 171.64 (+0.84), FLT: 149.45 (+0.27), EPAM: 46.69 (-0.26), REGN: 384.04 (+6.20), BABA: 116.05 (+1.49)
Recent News posted below.
Regeneron Pharmaceuticals REGN other info.
http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - 28 mins ago
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 384.04 (+6.20)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.25 (-0.08), SNY: 46.36 (+0.67), GNW: 8.33 (-0.08), REGN: 384.04 (+6.20)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 98.65 (+2.81), AMGN: 162.65 (+2.40), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 325.37 (+4.62), MNST: 106.81 (-1.58), ATI: 31.62 (-1.06), MON: 115.27 (+0.83), GMCR: 155.76 (+2.86), VMC: 65.16 (+0.05), EMR: 65.17 (+0.31), WDC: 97.40 (-0.30), VRSN: 60.51 (+0.71), URBN: 30.64 (-0.54), FSLR: 52.02 (+1.73), DE: 88.35 (-0.31), EXPE: 86.10 (+0.99), FLR: 66.20 (-0.09), FLS: 68.20 (+0.30), X: 36.98 (-0.59), ROK: 112.52 (+0.23), REGN: 384.04 (+6.20), MA: 84.97 (+0.17)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 116.76 (+0.83), GERN: 2.23 (-0.10), AMGN: 162.62 (+2.37), ABBV: 63.80 (+2.30), AEGR: 21.58 (unch), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 6:27PM CST
Regeneron Pharmaceuticals was down 6% today after releasing third-quarter earnings. While U.S. sales of its flagship drug Eylea rose 23% year over year in the third quarter and sales by its partner Bayer HealthCare outside the U.S. more than...
SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 5.79% Sell Off
Comtex SmarTrend(R) - Tue Nov 04, 3:51PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $368.45 to a high of $384.43. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $386.27 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 384.04 (+6.20)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.68 (-0.27), SNY: 46.36 (+0.67), REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 3:16PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 384.04 (+6.20)
Regeneron falls after paring Eylea sales outlook
AP - Tue Nov 04, 11:52AM CST
NEW YORK (AP) — Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue.
REGN: 384.04 (+6.20)
Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue Guidance
at The Street - Tue Nov 04, 10:10AM CST
Regeneron Pharmaceuticals (REGN) shares are falling following the release of its third quarter earnings report.
REGN: 384.04 (+6.20)
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter
at Investor's Business Daily - Tue Nov 04, 9:51AM CST
Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street's Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron's earnings,...
REGN: 384.04 (+6.20)
Stocks Tightly Mixed After Open; Alibaba Climbs On Q2 Results
at Investor's Business Daily - Tue Nov 04, 9:32AM CST
Stocks opened lower and quickly turned mixed Tuesday as earnings reports, soft oil prices and mixed economic data drove the bulk of early trade. The Dow Jones industrial average shed early losses and rose 0.1%. The Nasdaq narrowed its opening loss to...
HLF: 38.04 (+0.54), AFSI: 50.46 (+0.57), KORS: 69.49 (-0.46), FL: 54.70 (+0.20), REGN: 384.04 (+6.20), PCLN: 1,106.56 (+11.95), BABA: 116.06 (+1.50)
Regeneron Reports Third Quarter 2014 Financial and Operating Results
PR Newswire - Tue Nov 04, 5:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2014 and provided an update on development programs.
REGN: 384.04 (+6.20)
Big Cap 20: Health Care, Tech Stocks Rule The Roost
at Investor's Business Daily - Mon Nov 03, 4:58PM CST
Large-cap stocks often get labeled as boring because of overall sluggish price action, but the latest IBD Big Cap 20 list of leading large-cap growth is far from boring. Recent health care-related names like Alexion Pharmaceuticals (ALXN), Illumina...
LNKD: 227.73 (+4.69), ALXN: 194.86 (+1.05), ILMN: 189.51 (+3.16), REGN: 384.04 (+6.20), CRM: 63.80 (-0.17), CELG: 107.94 (+1.49)
Regeneron Announces Upcoming 2014 Investor Conference Presentations
PR Newswire - Mon Nov 03, 3:01PM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
REGN: 384.04 (+6.20)
Video: 4 Top-Rated Stocks Reporting Earnings Tuesday
at Investor's Business Daily - Mon Nov 03, 1:32PM CST
Alibaba, the world's largest IPO to date, is set to report its first quarterly earnings as a public company before the open on Tuesday. Analysts expect the Chinese e-commerce giant to earn 45 cents a share, excluding items, on revenue of $2.6...
JAZZ: 171.64 (+0.84), REGN: 384.04 (+6.20), BKW: 32.20 (-0.40), BABA: 116.06 (+1.50)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 86.77 (+2.86), ISIS: 45.99 (+1.40), SGEN: 36.16 (+0.11), GILD: 108.28 (+1.83), SSYS: 104.23 (+1.16), HP: 86.15 (-0.55), REGN: 384.04 (+6.20), CELG: 107.94 (+1.49)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 101.10 (+2.11), VRX: 127.62 (+1.51), BAX: 70.62 (+0.01), CVS: 88.94 (+0.56), REGN: 384.04 (+6.20)
Stocks End Week On Fine Note; LinkedIn Surges On Earnings
at Investor's Business Daily - Fri Oct 31, 3:29PM CDT
The market enjoyed another shot of institutional buying Friday, cheered by additional -- and unexpected -- stimulus measures by the Bank of Japan. Another round of healthy earnings reports and a rise in U.S. consumer confidence also fueled positive...
AMBA: 49.19 (+2.05), TSLA: 242.08 (+1.88), GPRO: 76.28 (-2.78), ACT: 247.66 (+1.75), FRGI: 56.39 (+0.80), LNKD: 227.73 (+4.69), JAZZ: 171.64 (+0.84), FLT: 149.45 (+0.27), EPAM: 46.69 (-0.26), REGN: 384.04 (+6.20), BABA: 116.05 (+1.49)
